Ledipasvir/Sofosbuvir (harvoni): improving options for hepatitis C virus infection.

Treatment with ledipasvir-sofosbuvir for hepatitis C resulting in improvement of lichen planus

DAA: direct antiviral agents HCV: hepatitis C virus LP: lichen planus INTRODUCTION Lichen planus (LP) is a chronic inflammatory disease affecting the skin and mucosa of squamous cell origin and has a significantly higher prevalence in patients infected with the hepatitis C virus (HCV). Although ribavirin-based treatments frequently show exacerbations of these lesions, currently there is little ...

Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature

BACKGROUND Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. As many clinical cases have reported, it may be associated with hepatitis C virus (HCV) infection. Antiviral therapy can be various. CASE SUMMARY We report a case of patient with chronic HCV infection and MN, who presented with was proteinuria. He was treated with ledipasvir and sofosbuvir (Harvon...

Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data

BACKGROUND Little is known on the cost-effectiveness of novel regimens for hepatitis C virus (HCV) compared with standard-of-care with pegylated interferon (pegIFN) and ribavirin (RBV) therapy in developing countries. We evaluated cost-effectiveness of sofosbuvir/ledipasvir for 12 weeks compared with a 48-week pegIFN-RBV regimen in Chinese patients with genotype 1b HCV infection by economic reg...

Once-a-Day Harvoni (Ledipasvir plus Sofosbuvir), a New Oral Combination for the Treament of Patients with Genotype 1 Chronic Hepatitis C Infection.

Successful Treatment of Necrolytic Acral Erythema with Ledipasvir and Sofosbuvir

Importance: Necrolytic Acral Erythema (NAE) is a cutaneous manifestation of hepatitis C virus infection, characterized by painful, unsightly lesions that tremendously diminish quality of life. Currently available treatments are minimally effective or difficult to tolerate. Additionally, interferon alpha, the most effective treatment to date, is contraindicated in patients with autoimmune diseas...